Cke Com USD0.01 (CKE) Quote

Is it monday yet dude!!!

Excellent

Drop the 'almost'. Sometimes association IS causation.

https://pubmed.ncbi.nlm.nih.gov/8500951/#:~:text=Though%20the%20standard%20of%20living,increase%20both%20poverty%20and%20inequality.

The record of economic well-being in the 1980s belied Reagan's claim that American

To me, all that is a no-brainer. Mr. T is methodical in his approach. That has worked to bring KBLB to where they are now and has brought the VSA, LAREC, and experts on board. I've said it for years, there will be an "Exponential Acceleration." When the time is right, Mr. T will deploy it. He's got

LG

BUT BUT BUT according to many here THERE ARE NO ASSETS !!!!!!!!!!!!!!
SO what were the "A" and "a" assets talked about?????????????

Or what were the assets spoken about in this quote ???????

"" Your Honor, The Assets Will Still Be There – The E

The problem is that most peeps think this is a big scam so we have to wait on the name change and other thing to convince peeps that this is the real deal then the price will shoot up dp it will take more time so we wait as usual but.........in the end this could turn out to be a scam but lets give

Yep, listening to these baggies, you would think old 83 YO Holcomb is smarter than Elon Musk. Lol. Too funny.

LOL. And NICE reimbursement in mid to late 2025. Be prepared for ongoing dilution for another year or two!

For a squeeze to take place, you need to have short sellers. They are virtually nonexistent with ELTP.

ARbigguy1, Thanks for that info. https://oig.hhs.gov/fraud/enforcement/drugmaker-nostrum-and-ceo-agree-to-pay-up-to-50-million-to-resolve-claims-of-underpaying-rebates-owed-under-medicaid-drug-rebate-program/

BSN Writing Services: Your Path to Academic Excellence in Nursing
Introduction
The journey to becoming a proficient nurse involves rigorous training, practical experiences, and extensive academic work. A Bachelor of Science in Nursing

First '10 out of 10', and 'woodies' to boot, that I've ever viewed from Chef Harsh Reviews.

abeWhat if the EMA is leaning towards approving our NDA...but hears that the FDA has already decided to turn us down? They can really muddy the waters for us.

Of course, all of these scenarios could be moot as long as the P2b/3 data and the OLE data is exceptional. THAT would be our g

Kudos!
To All: I stopped posting because I was so wrong about Rett outcome and believed what the company was telling us.
For accepting that learning and adjusting approach is beneficial - it is how it should be in the spirit of science. This is why biotech company's also present failed

Power2 the P1ayers Huzzah!🟩🟩

Don’t know how many times I have to say this: the company owns almost all of the stock including most of the float and will NOT let this thing run while it’s still named after a weed company. They define the pps at will. They hold it back and they prop it up. This channel is 100% artificial and has

Nostrum recently got hit with a $50 million fine! They are being watched closely by regulators and probably the justice department. That probably has a lot to do with the sale back to Elite.

I agree with you. No hiring on the commercial front is an indication that they expect the demand over the next year or so to be very low (close to Specials) OR a big pharma partner is waiting in the wings to take up GBM sales and in return provide a large influx of cash and percentage of ongoing sal

”GET READY SOMETHING COOL IS COMING”

Just like they had with Polartec, they could have a non-disclosure agreement in place with whoever that prevents the investing public from knowing who what where.

I think with Polartec, both sides got way out in front of their skii

Reading your Russian talking points.

I can wait til Tuesday! Lol

even though 1.2 million sounds like a lot of shares, it's not much money!

There is no real distinction between the corruption argument and the "beholden" argument as it relates to FDA decisional processes.

The Aduhelm approval was scandalous, but even that engendered public (SAB) and private (biostat division) opposition within the FDA, as well as resulting